Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityOther Accumulated ExpensesPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Payables (2016 - 2025)

Marker Therapeutics (MRKR) has disclosed Payables for 11 consecutive years, with $1.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Payables fell 34.91% to $1.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $1.7 million, a 34.91% decrease, with the full-year FY2024 number at $1.8 million, up 0.5% from a year prior.
  • Payables was $1.7 million for Q3 2025 at Marker Therapeutics, down from $2.3 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $7.3 million in Q1 2022 to a low of $1.7 million in Q3 2025.
  • A 5-year average of $3.0 million and a median of $2.3 million in 2023 define the central range for Payables.
  • Biggest YoY gain for Payables was 289.25% in 2022; the steepest drop was 65.36% in 2022.
  • Marker Therapeutics' Payables stood at $5.1 million in 2021, then crashed by 50.99% to $2.5 million in 2022, then crashed by 30.78% to $1.7 million in 2023, then grew by 0.5% to $1.8 million in 2024, then decreased by 5.09% to $1.7 million in 2025.
  • Per Business Quant, the three most recent readings for MRKR's Payables are $1.7 million (Q3 2025), $2.3 million (Q2 2025), and $2.1 million (Q1 2025).